prevalence of preexisting aav antibodies and implications for gene therapy in hemophilia
Published 5 years ago • 42 plays • Length 2:58Download video MP4
Download video MP3
Similar videos
-
20:57
overview of preexisting antibody testing prior to aav gene therapy presented by sarepta therapeutics
-
3:30
gene therapy data and implications of aav9 antibodies
-
2:23
current hurdles in aav-based gene therapy for hemophilia
-
1:57
aav gene therapies for hemophilia a and b
-
20:34
gene therapy for treatment of hemophilia: aav vector gene therapy application to hemophilia
-
5:50
long-term vector genome outcomes and immunogenicity of aav fviii gene transfer in hemophilia a
-
38:38
global seroprevalence of pre-existing immunity against aav5 and other aav serotypes
-
34:43
immunogenicity of aav vectors and transgenes - roland herzog
-
34:40
federico mingozzi: assessing and modulating immune responses to aav vectors in humans
-
4:15
synthetic aav vectors for gene therapy of hemophilia in children
-
0:57
aav gene transfer for hemophilia
-
28:50
gene therapy in hemophilia: common concerns in gene therapy
-
23:28
gene therapy for treatment of hemophilia: an introduction to aav vector gene transfer
-
36:32
gene therapy for fviii
-
35:20
interindividual variability in transgene mrna and protein production following aav gene therapy
-
2:25
hemophilia aav gene therapy animation
-
3:59
development of a clinical candidate aav3 vector for gene therapy of hemophilia b
-
3:07
aav-based gene therapy in hemophilia a and b: valoctocogene roxaparvovec & etranacogene dezaparvovec
-
1:04
gene therapy and antibodies